18 May 2013
Keywords: gsk, licences, hgs, lymphostat-b, uk, drug, major
Article | 18 July 2005
UK drug major GlaxoSmithKline has exercised its option to develop and commercialize a candidate treatment for rheumatoid arthritis and
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 July 2005
17 May 2013
© 2013 thepharmaletter.com